Edesa Biotech enrolls First Patient in COVID-19 Study of NI-0101 / EB05 (TLR4 anytibody).
Light Chain Bioscience has entered into two research collaborations and worldwide licensing agreements with Discoveric bio group.
Milestones achieved under research collaboration with LamKap Bio.
Antibodies being used as a T-cell targeting system to wipe out cancer cells.
CD47 is a potent “don’t eat me” signal that enables cancer cells to evade immune surveillance and killing by innate immune cells, such as macrophages.
